AstraZeneca (AZN) said Monday its investigational drug AZD0780 combined with standard-of-care statins reduced low-density lipoprotein, or LDL, cholesterol by 50.7% at 12 weeks in a phase 2b trial, with no need for fasting or food restrictions.

Among participants receiving AZD0780 30mg, 84% reached the recommended LDL-C target of under 70 mg/dL, compared with 13% on statins alone, the company said.

Elevated LDL-C is a known risk factor for serious cardiovascular conditions like heart attacks and strokes.

AZD0780 was generally well tolerated in the trial, with similar rates of adverse events and treatment discontinuation between the treatment and placebo groups, according to the company.

Price: 72.94, Change: -0.86, Percent Change: -1.16